The Effect of Levodopa on Vocal Function in Parkinson's Disease
Overview
Affiliations
Phonatory and articulatory dysfunctions are frequent observations in Parkinson's disease. We have investigated, using acoustic measures, the effects of levodopa treatment on vocal function in 20 patients with Parkinson's disease before and after levodopa. These patients were also compared with a matched control group. The mean age was 63.5 +/- 9.66 years, Hoehn-Yahr stage was 2.38 +/- 0.45, and onset mean age was 56.5 +/- 10.36 years. Paired Wilcoxon tests were performed to compare measurements before and after levodopa. The acoustic analysis using Computerized Speech Lab and MultiDimensional Voice Program software programs (Kay Elemetrics, Lincoln Park, NJ, USA) showed that measurements of fundamental frequency (p < 0.017) were significantly increased after medication, whereas short-term frequency perturbation jitter (p < 0.033), soft phonation index (noise parameter) (p < 0.015 ), and frequency tremor intensity index (p < 0.018) were significantly decreased after medication. The objective measurements of acoustic analysis are useful in evaluating the dopaminergic pharmacologic response in Parkinson's disease. The improvement in fundamental frequency and other vocal parameters may be a result of decrease in laryngeal hypokinesia and rigidity.
A neurocomputational view of the effects of Parkinson's disease on speech production.
Manes J, Bullock L, Meier A, Turner R, Richardson R, Guenther F Front Hum Neurosci. 2024; 18:1383714.
PMID: 38812472 PMC: 11133703. DOI: 10.3389/fnhum.2024.1383714.
Vocal and tongue exercise in early to mid-stage Parkinson disease using the Pink1-/- rat.
Hoffmeister J, Broadfoot C, Schaen-Heacock N, Lechner S, Krasko M, Nisbet A Brain Res. 2024; 1837:148958.
PMID: 38685371 PMC: 11166513. DOI: 10.1016/j.brainres.2024.148958.
Broadfoot C, Hoffmeister J, Lechner S, Krasko M, Lambert E, Russell J Behav Brain Res. 2023; 460:114754.
PMID: 37981125 PMC: 10872343. DOI: 10.1016/j.bbr.2023.114754.
Short-term effect of dopaminergic medication on speech in early-stage Parkinson's disease.
Tykalova T, Novotny M, Ruzicka E, Dusek P, Rusz J NPJ Parkinsons Dis. 2022; 8(1):22.
PMID: 35256614 PMC: 8901688. DOI: 10.1038/s41531-022-00286-y.
Speech dysfunction, cognition, and Parkinson's disease.
Rohl A, Gutierrez S, Johari K, Greenlee J, Tjaden K, Roberts A Prog Brain Res. 2022; 269(1):153-173.
PMID: 35248193 PMC: 11321444. DOI: 10.1016/bs.pbr.2022.01.017.